Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice

Neuropsychopharmacology

Volumn 31, Issue 9, 2006, Pages 1928-1937

  Kuzmin, Alexander ^a,b   Madjid, Nather ^a   Terenius, Lars ^a   Ogren, Sven Ove ^a   Bakalkin, Georgy ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anxiety; Big dynorphin; Dynorphin A; Dynorphin B; Memory; Mice

Indexed keywords

BUSPIRONE; DIAZEPAM; DIZOCILPINE; DYNORPHIN A; DYNORPHIN B; KAPPA OPIATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORBINALTORPHIMINE; PRODYNORPHIN;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MALE; MEMORY; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYNORPHINS; ENKEPHALINS; HEAT; MALE; MEMORY; MICE; MOLECULAR SEQUENCE DATA; MOTOR ACTIVITY; NALTREXONE; PAIN MEASUREMENT; PROTEIN PRECURSORS; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33747336771     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300959     Document Type: Article

References (62)

1. Bammer G (1982). Pharmacological investigations of neurotransmitter involvement in passive avoidance responding: a review and some new results. Neurosci Biobehav Rev 6: 247-296.
2. Bergink V, van Megen HJ, Westenberg HG (2004). Glutamate and anxiety. Eur Neuropsychopharmacol 14: 175-183.
3. Bodnar RJ, Klein GE (2004). Endogenous opiates and behavior. Peptides 25: 2205-2256.
4. Broadber JH, Negus SS, Butelman ER, deCosta BR, Woods JH (1994). Differential effects of systemically administered norbinaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology 115: 311-319.
5. Chang AC, Takemori AE, Portoghese PS (1994). 2-(3,4-Dichlorophenyl)-N- methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl) ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice. J Med Chem 37: 1547-1549.
6. Costigan M, Woolf CJ (2002). No DREAM, No pain. Closing the spinal gate. Cell 108: 297-300.
7. Day R, Akil H (1989). The posttranslational processing of prodynorphin in the rat anterior pituitary. Endocrinology 124: 2392-2405.
8. De Vries TJ, Shippenberg TS (2002). Neural systems underlying opiate addiction. J Neurosci 22: 3321-3325.
9. Drake CT, Terman GW, Simmons ML, Milner TA, Kunkel DD, Schwartzkroin PA et al (1994). Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J Neurosci 14: 3736-3750.
10. Endoh T, Matsuura H, Tanaka C, Nagase H (1992). Norbinaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316: 30-42.
11. Fallon JH, Leslie FM (1986). Distribution of dynorphin and enkephalin peptides in the rat brain. J Comp Neurol 249: 293-336.
12. File SE (2001). Factors controlling measures of anxiety and responses to novelty in the mouse. Behav Brain Res 125: 151-157.
13. Fischli W, Goldstein A, Hunkapiller MW, Hood LE (1982). Isolation and amino acid sequence analysis of a 4000-dalton dynorphin from porcine pituitary. Proc Natl Acad Sci USA 79: 5435-5437.
14. Gimenez-Llort L, Ferre S, Martinez E (1995). Effects of the systemic administration of kainic acid and NMDA on exploratory activity in rats. Pharmacol Biochem Behav 51: 205-210.
15. Graybiel AM (1990). The basal ganglia and the initiation of movement. Rev Neurol (Paris) 146: 570-574.
16. Griebel G, Belzung C, Misslin R, Vogel E (1993). The free exploratory paradigm: an effective method for measuring neophobic behavior in mice and testing potential neophobia reducing drugs. Behav Pharmacol 4: 637-644.
17. Hauser KF, Aldrich JV, Anderson KJ, Bakalkin G, Christie MJ, Hall ED et al (2005). Pathobiology of dynorphins in trauma and disease. Front Biosci 10: 216-235.
18. Hiramatsu M, Inoue K (2000). Des-tyrosine(1) dynorphin A-(2-13) improves carbon monoxide-induced impairment of learning and memory in mice. Brain Res 859: 303-310.
19. Hiramatsu M, Inoue K, Kameyama T (2000). Dynorphin A-(1-13) and (2-13) improve beta-amyloid peptide-induced amnesia in mice. Neuroreport 11: 431-435.
20. Hiramatsu M, Mori H, Murasawa H, Kameyama T (1996). Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats. Br J Pharmacol 118: 255-260.
21. Hiramatsu M, Murasawa H, Mori H, Kameyama T (1998). Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous κ-opioid receptor agonist. Br J Pharmacol 123: 920-926.
22. Horan P, Taylor J, Yamamura HI, Porreca F (1992). Extremely long-lasting anatagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharm Exp Ther 260: 1237-1243.
23. Itoh J, Ukai M, Kameyama T (1993). Dopaminergic involvement in the improving effects of dynorphin A-(1-13) on scopolamine-induced impairment of alternation performance. Eur J Pharmacol 241: 99-104.
24. Jackson A, Cooper SJ (1988). Observational analysis of the effects of kappa opioid agonists an open field behaviour in the rat. Psychopharmacology (Berlin) 94: 248-253.
25. Jones DNC, Holtzman SG (1992). Long term kappa-opioid receptor blockade following nor-binaltorphimine. Eur J Pharm 215: 345-348.
26. Kameyama T, Ukai M, Miura M (1994). Dynorphin A-(1-13) potently improves galanin-induced impairment of memory processes in mice. Neuropharmacology 33: 1167-1169.
27. Kaneko T, Nakazawa T, Ikeda M, Yamatsu K, Iwama T, Wada T et al (1983). Sites of analgesic action of dynorphin. Life Sci 33(Suppl 1): 661-664.
28. Khachaturian H, Watson SJ, Lewis ME, Coy D, Goldstein A, Akil H (1982). Dynorphin immunocytochemistry in the rat central nervous system. Peptides 3: 941-954.
29. Klintenberg R, Andren PE (2005). Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. J Mass Spectrom 40: 261-270.
30. Kreek MJ (2001). Drug addictions. Molecular and cellular end-points. Ann NY Acad Sci 937: 27-49.
31. Kreek MJ, LaForge KS, Butelman E (2002). Pharmacotherapy of addictions. Nat Rev Drug Discov 1: 710-726.
32. Kuzmin A, Sandin J, Terenius L, Ogren SO (2000). Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice. J Pharmacol Exp Ther 295: 1031-1042.
33. Lister RG (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180-185.
34. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H et al (1994). Mu, delta, and k-opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Neurol 350: 412-438.
35. Melani A, Corsi C, Gimenez-Llort L, Martinez E, Ogren SO, Pedata F et al (1999). Effect of N-methyl-D-aspartate on motor activity and in vivo adenosine striatal outflow in the rat. Eur J Pharmacol 385: 15-19.
36. Misane I, Ogren SO (2003). Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology 28: 253-264.
37. Nguyen XV, Masse J, Kumar A, Vijitruth R, Kulik C, Liu M et al (2005). Prodynorphin knockout mice demonstrate diminished age-associated impairment in spatial water maze performance. Behav Brain Res 161: 254-262.
38. Pierce JP, Kurucz OS, Milner TA (1999). Morphometry of a peptidergic transmitter system: dynorphin B-like immunoreactivity in the rat hippocampal mossy fiber pathway before and after seizures. Hippocampus 9: 255-276.
39. Privette TH, Terrian DM (1995). Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology (Berlin) 118: 444-450.
40. Reed B, Zhang Y, Chait BT, Kreek MJ (2003). Dynorphin A(1-17) biotransformation in striatum of freely moving rats using microdialysis and matrix-assisted laser desorption/ionization mass spectrometry. J Neurochem 86: 815-823.
41. Sandin J, Nylander I, Georgieva J, Schott PA, Ogren SO, Terenius L (1998). Hippocampal dynorphin B injections impair spatial learning in rats: a k-opioid receptor-mediated effect. Neuroscience 85: 375-382.
42. Sandin J, Tan-No K, Kasakov L, Nylander I, Winter A, Silberring J et al (1997). Differential metabolism of dynorphins in substantia nigra, striatum, and hippocampus. Peptides 18: 949-956.
43. Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA (2001). Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Ann NY Acad Sci 937: 50-73.
44. Solbrig MV, Koob G (2004). Epilepsy, CNS viral injury and dynorphin. Trends Pharmacol Sci 25: 98-104.
45. Tang Q, Gandhoke R, Burritt A, Hruby VJ, Porreca F, Lai J (1999). High-affinity interaction of (des-Tyrosyl) dynorphin A(2-17) with NMDA receptors. J Pharmacol Exp Ther 291: 760-765.
46. Tan-No K, Takahashi H, Nakagawasai O, Niijima F, Sato T, Sato S et al (2005). A pronociceptive role of dynorphins in uninjured animals: nociceptive effects of N-ethylmaleimide mediated through inhibition of degradation of endogenous dynorphins. Pain 113: 301-309.
47. Tan-No K, Esashi A, Nakagawasai O, Niijima F, Tadano T, Sakurada C et al (2002). Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism. Brain Res 952: 7-14.
48. Terman GW, Drake CT, Simmons ML, Milner TA, Chavkin C (2000). Opioid modulation of recurrent excitation in the hippocampal dentate gyrus. J Neurosci 20: 4379-4388.
49. Trujillo KA, Akil H (1991). Opioid and non-opioid behavioral actions of dynorphin A and the dynorphin analogue DAKLI. NIDA Res Monogr 105: 397-398.
50. Tsuda M, Suzuki T, Misawa M, Nagase H (1996). Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur J Pharmacol 307: 7-14.
51. Ukai M, Itoh J, Kobayashi T, Shinkai N, Kameyama T (1997). Effects of the k-opioid dynorphin A(1-13) on learning and memory in mice. Behav Brain Res 83: 169-172.
52. Ukai M, Shan-Wu X, Kobayashi T, Kameyama T (1996). Systemic administration of dynorphin A-(1-13) markedly improves cycloheximide-induced amnesia in mice. Eur J Pharmacol 313: 11-15.
53. Van Bockstaele EJ, Sesack SR, Pickel VM (1994). Dynorphin-immunoreactive terminals in the rat nucleus accumbens: cellular sites for modulation of target neurons and interactions with catecholamine afferents. J Comp Neurol 341: 1-15.
54. Vanderah TW, Laughlin T, Lashbrook JM, Nichols ML, Wilcox GL, Ossipov MH et al (1996). Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 68: 275-281.
55. Vincent S, Hökfelt T, Christensson I, Terenius L (1982). Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur J Pharmacol 85: 251-252.
56. Wagner JJ, Caudle RM, Chavkin C (1992). Kappa-opioids decrease excitatory transmission in the dentate gyrus of the guinea pig hippocampus. J Neurosci 12: 132-141.
57. Walker JM, Moises HC, Coy DH, Baldrighi G, Akil H (1982). Nonopiate effects of dynorphin and des-Tyr-dynorphin. Science 218: 1136-1138.
58. Wall PM, Messier C (2000). Concurrent modulation of anxiety and memory. Behav Brain Res 109: 229-241.
59. Wang Z, Gardell LR, Ossipov MH, Vanderah TW, Brennan MB, Hochgeschwender U et al (2001). Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 21: 1779-1786.
60. Xie GX, Goldstein A (1987). Characterization of big dynorphins from rat brain and spinal cord. J Neurosci 7: 2049-2055.
61. Xu M, Petraschka M, McLaughlin JP, Westenbroek RE, Caron MG, Lefkowitz RJ et al (2004). Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J Neurosci 24: 4576-4584.
62. Yu Y, Jawa A, Pan W, Kastin AJ (2004). Effects of peptides, with emphasis on feeding, pain, and behavior: a 5-year (1999-2003). Peptides 25: 2257-2289.